Locus Cell Past Earnings Performance
Past criteria checks 0/6
Locus Cell's earnings have been declining at an average annual rate of -52.6%, while the Life Sciences industry saw earnings growing at 21.2% annually. Revenues have been growing at an average rate of 61.5% per year.
Key information
-52.6%
Earnings growth rate
91.0%
EPS growth rate
| Life Sciences Industry Growth | 5.5% |
| Revenue growth rate | 61.5% |
| Return on equity | -5.3% |
| Net Margin | -23,865.5% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Locus Cell makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -97 | 79 | 61 |
| 30 Sep 23 | 0 | -77 | 76 | 56 |
| 30 Jun 23 | 1 | -72 | 68 | 49 |
| 31 Mar 23 | 1 | -66 | 63 | 41 |
| 31 Dec 22 | 1 | -53 | 61 | 32 |
| 30 Sep 22 | 1 | -44 | 57 | 21 |
| 30 Jun 22 | 0 | -54 | 57 | 13 |
| 31 Mar 22 | 0 | -44 | 44 | 6 |
| 31 Dec 21 | 0 | -35 | 32 | 2 |
Quality Earnings: 6891 is currently unprofitable.
Growing Profit Margin: 6891 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 6891's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 6891's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6891 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.6%).
Return on Equity
High ROE: 6891 has a negative Return on Equity (-5.31%), as it is currently unprofitable.